You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses and Publications

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

October 2021

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)

September 2021

Society of Hematologic Oncology (SOHO)

September 2021

Hematology Society of Australia and New Zealand (Blood)

September 2021

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2021 (Virtual)
September 2021

International Workshop on CLL (iwCLL)

September 2021

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2021 (Virtual)

Abstracts

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results

Most Recent Publications

 Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.  
 
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.